Molecular and therapeutic advances in the management of chronic hepatitis B and C.
Three hundred million individuals worldwide have persistent hepatitis B virus infection with 1-2 million hepatitis B virus-associated deaths per year, and an estimated 1% of the world's population are infected with hepatitis C virus. Recent advances in molecular biology and host responses have led to an increased understanding of hepatitis B and C virus disease and new potential targets for therapy.